Overall, the treatment outcomes and the observed safety profile with combination treatment with cobimetinib plus vemurafenib, were consistent with the pivotal phase 3 data in a population of patients with advanced melanoma and BRAF mutations [29,32]. This evidence concerns the gene BRAF and melanoma.